GlassScriptPhysician profile
Sharon Winer
NPI 1821456229
$449,352.87
in general payments reported to CMS, 2019-2025
11 companies · $53K in 2025
The $53K reported for 2025 was more than what 99% of Reproductive Endocrinology providers received nationally (typical 2025 total: $140).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $219K · 2020: $3,321 · 2021: $716 · 2023: $118K · 2024: $55K · 2025: $53K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $173K · Travel and Lodging: $37K · Honoraria: $8,970 · Food and Beverage: $7,652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $172,997.50 |
| Travel and Lodging | $36,739.65 |
| Honoraria | $8,970.00 |
| Food and Beverage | $7,651.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mayne Pharma Commercial LLC | $163,618.69 | 2023-2025 | |
| Abbvie INC. | $133,848.99 | 2019-2020 | |
| Therapeuticsmd, INC. | $88,195.68 | 2019-2020 | |
| Astellas Pharma US INC | $62,586.65 | 2023-2025 | Veozah |
| Lupin INC. | $700.00 | 2021 | |
| Coopersurgical, INC. | $168.69 | 2019 | |
| Novo Nordisk INC | $120.85 | 2024 | Wegovy |
| Amag Pharmaceuticals, INC. | $64.47 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.46 | 2025 | |
| Myovant Sciences INC. | $16.25 | 2021 | |
| Astellas Pharma Global Development | $15.14 | 2023 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Winer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.